

M34-A

Western Blot Assay for Antibodies to *Borrelia burgdorferi*; Approved Guideline

SAMPLE

This document addresses technical and interpretive considerations for use of Western blot assays that detect antibodies to *Borrelia burgdorferi* and other *Borrelia* species that cause Lyme disease.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org

NOTE: This document is no longer being reviewed as part of the CLSI consensus process. However, because of its usefulness to segments of the health care community, it is available for its informational content.

ISBN 1-56238-415-5
ISSN 0273-3099

M34-A
Vol. 20 No. 20
Replaces M34-P
Vol. 18 No. 12

Western Blot Assay for Antibodies to *Borrelia burgdorferi*; Approved Guideline

Volume 20 Number 20

Alan G. Barbour, M.D., Chairholder
Barbara Johnson, Ph.D.
Barry E. Menefee, Ph.D.
David H. Persing, M.D., Ph.D.
Ronald F. Schell, Ph.D.
Roxanne G. Shively, M.S.
Arthur Weinstein, M.D.

Abstract

Clinical and Laboratory Standards Institute document M34-A—*Western Blot Assay for Antibodies to Borrelia burgdorferi*; *Approved Guideline* is intended for use as a critical tool in the diagnosis of Lyme disease for laboratorians who perform Western blot assays within clinical and reference laboratories. The document addresses the advantages and disadvantages of Western blot assays; antigen preparation; electrophoresis of antigens; transfer of antigens to the matrix; calibration of blots; quality control and proficiency testing; scoring the blot; reporting the results; and interpretation of the report. While the document specifically deals with Western blot assays for antibodies to *Borrelia burgdorferi* in the diagnosis of Lyme disease, the document's generic recommendations are applicable to other situations in which Western blot assays are applied in the clinical or reference laboratory.

Clinical and Laboratory Standards Institute (CLSI). *Western Blot Assay for Antibodies to Borrelia burgdorferi*; *Approved Guideline*. CLSI document M34-A (ISBN 1-56238-415-5). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2000.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.

Copyright ©2000 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Western Blot Assay for Antibodies to Borrelia burgdorferi; Approved Guideline*. CLSI document M34-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2000.

Proposed Guideline

September 1998

Approved Guideline

October 2000

ISBN 1-56238-415-5
ISSN 0273-3099

Contents

Abstract.....	i
Committee Membership.....	iii
Active Membership.....	v
Foreword.....	xiii
1 Introduction.....	1
1.1 Principle.....	1
1.2 Scope.....	2
1.3 Definitions.....	2
1.4 Advantages.....	5
1.5 Limitations.....	6
2 Preparation of Antigens.....	6
2.1 General Considerations.....	6
2.2 Choice of Strain for Antigen Preparations.....	7
2.3 Growth Conditions for <i>B. burgdorferi</i>	7
2.4 Demonstration that a Culture of <i>B. burgdorferi</i> is Pure at Harvest.....	8
2.5 Preparation of <i>B. burgdorferi</i> Cell Lysates.....	8
3 Separation of Antigen Constituents by SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE).....	9
3.1 General Considerations.....	9
3.2 SDS-PAGE of <i>B. burgdorferi</i>	9
4 Transferring the Antigens, Blocking the Membrane, Incubating the Specimen, and Developing the Blot.....	10
4.1 Transfer of Antigens to the Membrane.....	10
4.2 Blot Preparation.....	10
4.3 Suitable Samples.....	11
4.4 Dilution of Samples.....	11
4.5 Assay Conditions.....	11
4.6 Blot Development.....	12
4.7 Blot Considerations Specific for <i>B. burgdorferi</i> and Lyme Disease.....	12
5 Calibration of Blots.....	13
6 Quality Control and Proficiency Programs.....	13
7 Scoring the Blot and Reporting the Results.....	15
8 Interpretation of the Report.....	16
8.1 Predictive Value of a Positive and Negative Western Blot.....	17
8.2 Use of the Western Blot Test to Detect Antibodies in Clinical Practice, Epidemiological Surveys, and Research.....	17
References.....	19
Additional References.....	21

Contents (Continued)

Summary of Comments and Subcommittee Responses.....22

Summary of Delegate Comments and Responses.....23

Related NCCLS Publications.....24

SAMPLE

Foreword

The intended audience for M34-A—*Western Blot Assay for Antibodies to Borrelia burgdorferi; Approved Guideline*, is clinical and reference laboratories that perform Western blot assays for antibodies. The document details technical and interpretive considerations for use of Western blot assays for antibodies to *Borrelia burgdorferi* and other *Borrelia* species that cause Lyme disease. The outline of M34-A and its generic methodological considerations may also be applicable to the use of Western blot assays for detecting antibodies to other microorganisms or antigens.

The Western blot assay for antibodies was first widely used as a second-tier test method for detecting specific antibodies or confirmatory assay for the detection of antibodies to HIV. In this role, the Western blot assay was used as a highly specific assay with which to further evaluate a positive or borderline reaction in an enzyme immunoassay (EIA). With this rationale, the Western blot assay has been applied as a second-tier test for antibodies to *Borrelia burgdorferi* to provide serologic evidence to aid in the diagnosis of Lyme disease. In a situation in which a very complex set of antigens from whole bacteria was used instead of a handful of antigens from a retrovirus, the difficulties and challenges of the Western blot assay became more apparent. The increased use of the assay and increased dependence on results for providing diagnostic evidence of infection has caused considerable confusion with performance of the assay and interpretation of its results.

This document provides a set of recommendations to minimize, if not eliminate, these difficulties. It also provides a framework for setting national or international guidelines for performing and interpreting Western blot assays detecting antibodies to *Borrelia burgdorferi*. While it has been noted that differences in interpretation of the Western blot assay used for diagnosis of Lyme disease exist between North America and Europe, it is the subcommittee's intention to make every effort to foster harmonization in interpretation in future versions of M34. To begin to fill this identified void in standardization, the Area Committees on Microbiology and Molecular Methods will seek opportunities to develop guidelines and standards for the performance and interpretation of Western blot assays that have applicability to a broad variety of antibodies to other organisms and antigens for application worldwide.

Key Words

Antibody, antigen, Western blot assay

Western Blot Assay for Antibodies to *Borrelia burgdorferi*; Approved Guideline

1 Introduction

1.1 Principle

The Western blot or immunoblot assay is a qualitative or semiquantitative immunologic test for antibody to a nonself- or self-antigen. It has six steps:

- (1) one-dimensional electrophoretic separation of antigens (proteins, carbohydrates, and/or lipids) primarily on the basis of molecular size;
- (2) capillary or electrophoretic transfer of the separated components to a solid matrix, usually a microporous membrane;
- (3) blocking of uncomplexed protein-binding sites on the membrane;
- (4) incubation of the blocked membrane with antibodies in a body fluid, usually serum or cerebrospinal fluid, that is suspected of containing antibodies to antigens on the membrane;
- (5) colorimetric, fluorescent, chemiluminescent, phosphorescent, radiometric, or electronic detection of the bound antibodies on the membrane by using labeled second antibody or other ligand with specificity for the immunoglobulins (usually IgM and IgG) of interest; and
- (6) visual assessment or image analysis of the developed blot, identification of the detected antibody-antigen complexes on the blot using antigen standards, and comparison of the reactions of clinical specimens to reactions of positive and negative control specimens.

Material of various degrees of complexity is subjected to electrophoretic separation in the first step. Lysed material may be whole cells, viruses, organelles, subunit fractions, or combinations of recombinant-derived antigens of infectious agents, allergens, or animal tissues.

The test result is the binding or lack of binding to a combination of selected antigens in the electrophoretically separated sample. Identification of bands that are observed in the developed blot depends either on monospecific antibodies to the selected antigens or purified preparations of native or recombinant forms of the selected antigens run in parallel on the gel. A Western blot test is usually interpreted as “positive” when a certain number of the selected antigens are represented as bands of a minimum intensity on the developed membrane, photographic film, or digital image. The Western blot assay is usually but not always performed for immunological testing for infectious diseases and autoimmune diseases as a highly specific assay for antibodies after a screening or otherwise highly sensitive antibody assay, such as EIA.

The Western blot assay, like other antibody assays used as a second step or supplemental procedure, has its highest positive predictive value when the *a priori* likelihood of the disease is high on the basis of clinical and epidemiologic criteria. The negative predictive value of the Western blot will also vary according to the population tested; because of the variability of the antibody response among infected individuals, it cannot be as well-defined clinically as the positive predictive value of the assay.

1.2 Scope

M34-A is intended to serve as an adjunct in the serologic diagnosis of Lyme disease. To achieve this goal, this guideline presents a comprehensive test methodology for the performance of the Western blot assay for antibodies against the organism *Borrelia burgdorferi* and other *Borrelia* spp. which have been implicated as causative agents of Lyme disease. The Western blot methods outlined within M34-A also have broad applicability over a range of other antigens and antibodies. While the interpretive guidelines contained in M34-A are specific to *Borrelia* species that cause disease in endemic areas in North America, it is anticipated that future expansion of these guidelines to address *Borrelia* species implicated as Lyme etiologic agents in other areas of the world outside of the United States will foster further global harmonization of these methods.

1.3 Definitions^a

Accuracy// Measurement accuracy// Accuracy of measurement, *n* - Closeness of the agreement between the result of a measurement and a true value of the measurand {/analyte}.

Affinity, *n* - A measure of the attraction, or force of association, between a single antigenic site and a single antibody to that site; **NOTE:** a) The affinity constant is usually expressed as the equilibrium constant for the receptor + ligand reaction. Because of their heterogeneity, average or mean affinity constants are usually described for polyclonal antisera.

Antibody, *n* - The functional component of antiserum, composed of a population of Y-shaped protein molecules, each member of which is capable of reacting with (binding to) a specific antigenic determinant.

Antigen, *n* - Any substance that can stimulate the production of antibodies by an organism and combine specifically with them.

Epitope//antigenic determinant//(determinant), *n* - 1) The minimum molecular structure of the antigenic site that will react with a monoclonal antibody; 2) Any site on an antigen molecule at which an antibody can bind; the chemical structure of the site determining the specific combining antibody.

Antiserum, *n* - A serum produced in animals or human beings that contains antibodies to one or more antigens of interest.

Band, *n* - A discrete region of the developed Western blot that corresponds to an antigen of a particular molecular size and the binding of antibody to that antigen.

Blocking, *n* - The reaction of uncomplexed binding sites or of coupling agents to prevent nonspecific binding of test reactants.

Blot development, *n* - The detection of the binding of antibody to an antigen on the blot by colorimetric, fluorescent, phosphorescent, chemiluminescent, radiometric, or electronic signal.

Conjugate, *n* - A material produced by attaching two or more substances together.

Control//Control material, *n* - A device, solution, or lyophilized preparation intended for use in the quality control process.

^a Some of these definitions are found in NCCLS document NRSL8—*Terminology and Definitions for Use in NCCLS Documents*. For complete definitions and detailed source information, please refer to the most current edition of that document.

Related NCCLS Publications*

- I/LA18-A** **Specifications for Immunological Testing for Infectious Diseases; Approved Guideline (1994).** This guideline outlines specimen requirements; performance criteria; algorithms for the potential use of sequential or duplicate testing; recommendations for intermethod comparisons of immunological test kits for detecting infectious diseases; and specifications for development of reference materials.
- NRSCL8-A** **Terminology and Definitions for Use in NCCLS Documents; Approved Standard (1998).** This document provides standard definitions for use in NCCLS standards and guidelines, and for submitting candidate reference methods and materials to the National Reference System for the Clinical Laboratory (NRSCL).

SAMPLE

* Proposed- and tentative-level documents are being advanced through the NCCLS consensus process; therefore, readers should refer to the most recent editions.



Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we're adding initiatives to bring even more value to our members and customers.



Shop Our Online Products

Including eM100, the interactive searchable database for drug selection, interpretation, and quality control procedures within M100-S23.



Find Membership Opportunities

See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.



Visit the CLSI U Education Center

Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.



Shop Our Online Products

Including eCLIPSE Ultimate Access™, CLSI's cloud-based, online portal that makes it easy to access our standards and guidelines—*anytime, anywhere.*

For more information, visit www.clsi.org today.

SAMPLE



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

950 West Valley Road, Suite 2500, Wayne, PA 19087 USA

P: 610.688.0100 Toll Free (US): 877.447.1888 F: 610.688.0700

E: customerservice@clsi.org www.clsi.org

ISBN 1-56238-415-5